For a rising portfolio

Learn everything you need to know in 'How to Find the Best Growth Stocks' for FREE from The Successful Investor.

Canadian Growth Stocks: CGI Group, CAE Inc., Fortis Inc. Stock and more.

 I consent to receiving information from The Successful Investor via email. I understand I can unsubscribe from these updates at any time.

Topic: Growth Stocks

BAXTER INTERNATIONAL INC. $66 – New York symbol BAX

BAXTER INTERNATIONAL INC. $66 (New York symbol BAX; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 549.4 million; Market cap: $36.3 billion; Price-to-sales ratio: 2.6; Dividend yield: 2.7%; TSINetwork Rating: Average; www.baxter.com) makes medical products, such as intravenous pumps and kidney dialysis equipment. It also makes vaccines and drugs. Half of its sales come from single-use products that need to be continually reordered.

Demand for the company’s products continues to improve, particularly as an aging population needs more medical devices and drugs. Baxter’s sales rose 23.4%, from $11.3 billion in 2007 to $13.9 billion in 2011.

Earnings rose 36.1%, from $1.8 billion in 2007 to $2.5 billion in 2011. The company is an aggressive buyer of its own shares. Because of a 10% drop in the number of shares outstanding, earnings per share jumped 54.5%, from $2.79 to $4.31.

Research spending is key to growth

A big part of the company’s success comes from its ability to develop new products. Baxter spent a record $946 million (or 6.8% of its sales) on research in 2011. That’s up 3.4% from $915 million (or 7.1% of sales) in 2010.

To complement its own research, Baxter set aside $200 million in 2011 to help smaller companies working on new drugs. As part of this plan, Baxter invested $50 million in Onconova Therapeutics, a Pennsylvania- based private firm that has developed a new intravenous pancreatic cancer drug called Rigosertib. This treatment is now undergoing clinical trials.

Baxter later agreed to pay an additional $50 million for the European rights to Rigosertib. If regulators approve the drug, the company may have to pay a further $515 million.

Rigosertib nicely complements Baxter’s existing anti-cancer drugs. The company can also use its extensive salesforce to promote Rigosertib to clients who already buy its intravenous equipment.

Acquisitions play a significant role

The company also uses acquisitions to enhance its growth. For example, in February 2012 it paid $304 million for Synovis Life Technologies, which makes patches and surgical tools to treat burns other wounds.

Baxter can easily afford to keep expanding. On September 30, 2012, its long-term debt was $5.6 billion, or just 15% of its market cap. It also held cash of $3.2 billion, or $5.86 a share.

The company should earn $4.53 a share in 2012, and the stock trades at 14.6 times that estimate. The $1.80 dividend yields 2.7%.

New regulations a minor worry

Obamacare in the U.S. will force Baxter to pay a 2.3% tax on the sales of certain medical devices. Government regulators will also likely pressure Baxter and other medical suppliers to cut their prices.

However, the U.S. accounts for just 40% of Baxter’s sales. Moreover, it feels its sales will rise 5% a year to 2017. It also projects that its annual earnings per share will grow 7% to 9% over this period.

Baxter is a buy.

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.